SNDX Insider Trading Activity and SEC Form 4 Filings
SNDX insider trading summary
Over the past 12 months, insiders at Syndax Pharmaceuticals Inc (SNDX) reported 10 sales worth $2.9M by 4 insiders and no open-market purchases on SEC Form 4. Net insider selling was $2.9M.
Latest SNDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 29, 2026 | Dennis Podlesak | Insider | Sell | $114K (8,000 @ $14.21) |
| Jul 8, 2026 | Michael A Metzger | Chief Executive Officer | Sell | $785K (32,375 @ $24.24) |
| Jun 12, 2026 | Nicholas A.J. Botwood | Head of R&D, CMO | Sell | $567K (31,235 @ $18.14) |
| Jun 11, 2026 | Nicholas A.J. Botwood | Head of R&D, CMO | Sell | $617K (34,280 @ $18.00) |
| Jun 1, 2026 | Keith A. Goldan | Chief Financial Officer | Sell | $22K (1,177 @ $18.99) |
| Jun 1, 2026 | Michael A Metzger | Chief Executive Officer | Sell | $130K (6,847 @ $18.99) |
| Feb 9, 2026 | Keith A. Goldan | Chief Financial Officer | Sell | $72K (3,410 @ $21.03) |
| Feb 9, 2026 | Michael A Metzger | Chief Executive Officer | Sell | $361K (17,159 @ $21.03) |
| Feb 6, 2026 | Keith A. Goldan | Chief Financial Officer | Sell | $43K (2,082 @ $20.62) |
| Feb 6, 2026 | Michael A Metzger | Chief Executive Officer | Sell | $153K (7,412 @ $20.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.